Created at	Source	Raw Value	Validated value
June 28, 2023, 4 a.m.	usa	Anti-MenACWY IgG concentrations at study end;Anti-S1 and anti-RBD IgG concentrations against SARS-COV-2 at study end;Baseline anti-strike (S1) immunoglobulin (IgG) and anti-receptor-binding domain (RBD) IgG concentrations against severe acute respiratory syndrome (SARS)-Coronavirus (COV)-2;Baseline IgG concentration against meningococcal serogroups A, C, W, and Y (anti-MenACWY IgG)	Anti-MenACWY IgG concentrations at study end;Anti-S1 and anti-RBD IgG concentrations against SARS-COV-2 at study end;Baseline anti-strike (S1) immunoglobulin (IgG) and anti-receptor-binding domain (RBD) IgG concentrations against severe acute respiratory syndrome (SARS)-Coronavirus (COV)-2;Baseline IgG concentration against meningococcal serogroups A, C, W, and Y (anti-MenACWY IgG)